BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 1321281)

  • 1. Epstein-Barr virus (EBV)-negative B-lymphoma cell lines for clonal isolation and replication of EBV recombinants.
    Marchini A; Longnecker R; Kieff E
    J Virol; 1992 Aug; 66(8):4972-81. PubMed ID: 1321281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A selectable marker allows investigation of a nontransforming Epstein-Barr virus mutant.
    Marchini A; Cohen JI; Wang F; Kieff E
    J Virol; 1992 May; 66(5):3214-9. PubMed ID: 1313925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr virus (EBV) recombinants: use of positive selection markers to rescue mutants in EBV-negative B-lymphoma cells.
    Wang F; Marchini A; Kieff E
    J Virol; 1991 Apr; 65(4):1701-9. PubMed ID: 1848303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus recombinants from overlapping cosmid fragments.
    Tomkinson B; Robertson E; Yalamanchili R; Longnecker R; Kieff E
    J Virol; 1993 Dec; 67(12):7298-306. PubMed ID: 8230453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-site homologous recombination in Epstein-Barr virus: insertion of type 1 EBNA 3 genes in place of type 2 has no effect on in vitro infection.
    Tomkinson B; Kieff E
    J Virol; 1992 Feb; 66(2):780-9. PubMed ID: 1309912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Epstein-Barr virus with a 58-kilobase-pair deletion that includes BARF0 transforms B lymphocytes in vitro.
    Robertson ES; Tomkinson B; Kieff E
    J Virol; 1994 Mar; 68(3):1449-58. PubMed ID: 8107208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Epstein-Barr virus BamHI F promoter is an early lytic promoter: lack of correlation with EBNA 1 gene transcription in group 1 Burkitt's lymphoma cell lines.
    Schaefer BC; Strominger JL; Speck SH
    J Virol; 1995 Aug; 69(8):5039-47. PubMed ID: 7609074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of bcl-2 in Burkitt's lymphoma cell lines: induction by latent Epstein-Barr virus genes.
    Finke J; Fritzen R; Ternes P; Trivedi P; Bross KJ; Lange W; Mertelsmann R; Dölken G
    Blood; 1992 Jul; 80(2):459-69. PubMed ID: 1378321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.
    Lear AL; Rowe M; Kurilla MG; Lee S; Henderson S; Kieff E; Rickinson AB
    J Virol; 1992 Dec; 66(12):7461-8. PubMed ID: 1331531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reducing the complexity of the transforming Epstein-Barr virus genome to 64 kilobase pairs.
    Robertson E; Kieff E
    J Virol; 1995 Feb; 69(2):983-93. PubMed ID: 7815566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
    Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
    Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient EBV superinfection of group I Burkitt's lymphoma cells distinguishes requirements for expression of the Cp viral promoter and can activate the EBV productive cycle.
    Evans TJ; Jacquemin MG; Farrell PJ
    Virology; 1995 Feb; 206(2):866-77. PubMed ID: 7856099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcription of the Epstein-Barr virus nuclear antigen 1 (EBNA1) gene occurs before induction of the BCR2 (Cp) EBNA gene promoter during the initial stages of infection in B cells.
    Schlager S; Speck SH; Woisetschläger M
    J Virol; 1996 Jun; 70(6):3561-70. PubMed ID: 8648690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential regulation of Epstein-Barr virus (EBV) latent gene expression in Burkitt lymphoma cells infected with a recombinant EBV strain.
    Trivedi P; Spinsanti P; Cuomo L; Volpe M; Takada K; Frati L; Faggioni A
    J Virol; 2001 May; 75(10):4929-35. PubMed ID: 11312367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus recombinants from BC-1 and BC-2 can immortalize human primary B lymphocytes with different levels of efficiency and in the absence of coinfection by Kaposi's sarcoma-associated herpesvirus.
    Aguirre AJ; Robertson ES
    J Virol; 2000 Jan; 74(2):735-43. PubMed ID: 10623735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus nuclear protein 2 is a critical determinant for tumor growth in SCID mice and for transformation in vitro.
    Cohen JI; Picchio GR; Mosier DE
    J Virol; 1992 Dec; 66(12):7555-9. PubMed ID: 1331538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different patterns of Epstein-Barr virus gene expression and of cytotoxic T-cell recognition in B-cell lines infected with transforming (B95.8) or nontransforming (P3HR1) virus strains.
    Murray RJ; Young LS; Calender A; Gregory CD; Rowe M; Lenoir GM; Rickinson AB
    J Virol; 1988 Mar; 62(3):894-901. PubMed ID: 2828684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.
    Wang F; Gregory C; Sample C; Rowe M; Liebowitz D; Murray R; Rickinson A; Kieff E
    J Virol; 1990 May; 64(5):2309-18. PubMed ID: 2157887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein.
    Abbot SD; Rowe M; Cadwallader K; Ricksten A; Gordon J; Wang F; Rymo L; Rickinson AB
    J Virol; 1990 May; 64(5):2126-34. PubMed ID: 2157875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of integrated Epstein-Barr virus nuclear antigen 1 and 2 genes in a Burkitt lymphoma cell line after somatic cell fusion with autologous EBV-immortalized lymphoblastoid cells.
    Wolf J; Pawlita M; Klevenz B; Frech B; Freese UK; Müller-Lantzsch N; Diehl V; zur Hausen H
    Int J Cancer; 1993 Feb; 53(4):621-7. PubMed ID: 8382194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.